Inhibrx, Inc. (NASDAQ: INBX) is a clinical-stage biotechnology company headquartered in San Diego, California, focused on developing novel therapeutic proteins using its proprietary single-domain antibody (sdAb) and multi-specific antibody platforms. The company is applying its technology to generate treatments for oncology, immunology, and neurodegenerative diseases["@inhibrx"].
...
Overview
Mermaid diagram (expand to render)
Inhibrx, Inc. (NASDAQ: INBX) is a clinical-stage biotechnology company headquartered in San Diego, California, focused on developing novel therapeutic proteins using its proprietary single-domain antibody (sdAb) and multi-specific antibody platforms. The company is applying its technology to generate treatments for oncology, immunology, and neurodegenerative diseases["@inhibrx"].
Founded in 2010, Inhibrx has built a differentiated platform based on camelid-derived single-domain antibodies (nanobodies), which offer unique properties including small size, high affinity, stability, and the ability to engage multiple targets simultaneously["@sdib"].
INBRX-101 is a single-domain antibody targeting alpha-synuclein aggregates for Parkinson's disease and related disorders. The sdAb platform offers advantages in tissue penetration and clearance of aggregated proteins[@inbrx].
Mechanism of Action:
Binds to alpha-synuclein aggregates
Promotes clearance via Fc-mediated mechanisms
Blocks cell-to-cell transmission
Prevents aggregation seeding
Advantages of sdAb Platform:
Small size (~12 kDa)
High affinity and specificity
Excellent tissue penetration
Stable and manufacturable
Multiple binding modalities
Development Status:
Preclinical development
IND-enabling studies planned
Focus on Parkinson's disease
INBRX-105 (Tau)
INBRX-105 is a tau-targeting single-domain antibody in preclinical development for Alzheimer's disease. The program leverages the same sdAb platform as INBRX-101[@alphasynuclein2024].